Each year, ESHRE brings together research spanning clinical practice, embryology, fertility preservation, genetics, artificial intelligence, and laboratory innovation.

As we reviewed the studies presented at ESHRE 2026, what stood out was not one entirely new technology.

Instead, many studies explored how existing tools, growing datasets, and established clinical practices could be used more precisely to support better decisions.

This is not intended to be a complete summary of the congress.

Rather, it is our reading of several notable studies through four recurring themes:

Safe decisions through single embryo transfer
Personalized decisions in fertility preservation
Trustworthy decisions supported by fit-for-purpose AI
Genomics-informed decisions based on more nuanced interpretation

1. Safe decisions: redefining success through single embryo transfer

Study highlighted

Modern IVF clinical practices achieve superior cumulative live birth rates with near-universal single embryo transfer: A multi-cycle cohort study

View the abstract

What stood out

Single embryo transfer has long been recommended to reduce the risks associated with multiple pregnancy.

A practical concern, however, has often been whether prioritizing safety could come at the cost of treatment success.

This large multi-cycle cohort study offered a different perspective.

A near-universal single embryo transfer strategy was accompanied by strong cumulative live birth outcomes and a low multiple birth rate.

The findings suggest that single embryo transfer may not need to be viewed solely as a trade-off between safety and success.

Advances in blastocyst culture, vitrification, embryo selection, and frozen embryo transfer are making it increasingly possible to pursue both across a complete course of treatment.

Our takeaway

The definition of IVF success appears to be broadening.

Rather than focusing only on pregnancy from a single transfer, the goal is increasingly to achieve a healthy live birth safely while considering the cumulative outcome of treatment.

From this perspective, single embryo transfer is becoming less of a compromise and more of a strategy aligned with both reproductive safety and long-term treatment success.

2. Personalized decisions: planning fertility preservation around age and realistic outcomes

Study highlighted

Age-related outcomes after planned oocyte cryopreservation: a 12-year national cohort study of over 12,000 cycles

View the abstract

What stood out

Planned oocyte cryopreservation is often discussed as a way to preserve future reproductive options.

However, its potential value depends heavily on when oocytes are frozen and what outcomes can realistically be expected later.

This national cohort study drew on more than 12 years of clinical data to examine how planned oocyte cryopreservation outcomes varied according to age.

The findings add real-world evidence to a question that is increasingly relevant in fertility counselling.

The practical discussion is therefore moving beyond whether someone should consider oocyte freezing.

It is also about when the procedure is most likely to provide meaningful future options and how expectations should be communicated at different ages.

Our takeaway

Fertility preservation is not simply a technical procedure.

Its value also depends on helping each patient understand how age, expected oocyte yield, future use, and the probability of success fit together.

More individualized counselling may therefore become as important as the freezing procedure itself.

The aim is not only to preserve oocytes, but to help patients make better-informed decisions about timing and future reproductive planning.

3. Trustworthy decisions: AI should be judged by purpose and validation

Study highlighted

Can free-access general-purpose AI platforms reliably predict IVF outcomes? A benchmarking study of image-based embryo interpretation against live-birth results

View the abstract

What stood out

AI was highly visible across the ESHRE 2026 programme.

One study, however, raised an important distinction by evaluating whether freely available general-purpose AI platforms could reliably predict IVF outcomes from embryo images.

The results suggested that these platforms were not sufficiently reliable for direct clinical prediction.

This does not mean that AI has no role in IVF. Instead, it highlights why different types of AI should not be treated as interchangeable.

A general-purpose platform is designed to respond across a wide range of subjects and tasks.

Medical AI, by contrast, should be developed for a clearly defined clinical purpose, trained on relevant data, and evaluated against outcomes that reflect its intended use.

Our takeaway

The important question is not simply whether a system uses AI.

What matters is what the system was designed to do, which data were used to develop it, whether it has been validated in the relevant clinical setting, and how its outputs are incorporated into professional decision-making.

For IVF, trustworthy AI is likely to depend less on broad claims of intelligence and more on domain-specific development, clinical validation, transparency, and a clearly defined role alongside clinicians and embryologists.

4. Genomics-informed decisions: moving beyond binary classifications

Studies highlighted

Chromosome-specific pregnancy outcomes after mosaic embryo transfer: disentangling abnormality severity from chromosome identity

View the abstract

Clinical utility and efficiency of abnormally fertilized oocytes derived blastocysts in PGT-M cycles

View the abstract

What stood out

Several studies at ESHRE 2026 reflected a broader shift in embryo genetics: from simply detecting abnormalities toward interpreting genetic findings in a more clinically meaningful way.

The first study examined pregnancy outcomes after mosaic embryo transfer by considering not only the severity of mosaicism, but also the chromosome involved.

Its findings suggest that mosaic embryos may not always be adequately understood through a single transferable-or-non-transferable category.

The second study examined blastocysts derived from abnormally fertilized oocytes in PGT-M cycles.

Although their overall clinical contribution may be limited, the study explored whether selected embryos from these oocytes could still provide an additional reproductive opportunity when appropriately evaluated through PGT.

Together, these studies illustrate how embryo genetics is becoming more interpretive. The question is increasingly not only whether an abnormality is present, but what that finding may mean for a particular embryo and clinical situation.

Our takeaway

The future value of PGT may depend not only on identifying genetic abnormalities, but also on interpreting their clinical relevance and using available information to support more individualized decisions.

This could include assessing mosaic embryos with greater nuance and reconsidering whether some embryos that would previously have been excluded may retain limited clinical utility in carefully selected circumstances.

The direction appears to be moving away from simple binary classifications and toward more detailed, context-dependent interpretation.

From more technology to better decisions

These four themes represent only one reading of the extensive research presented at ESHRE 2026.

Still, they suggest that the next phase of IVF innovation may be shaped less by how much technology or data is available and more by how effectively they are translated into clinical decisions.

Single embryo transfer is being considered through both cumulative success and reproductive safety.
Fertility preservation is becoming more closely tied to age, realistic expectations, and individualized counselling.
AI is being judged by its intended purpose, clinical validation, and trustworthiness rather than novelty alone.
Genetic information is being interpreted with increasing nuance instead of being reduced to binary categories.

Our main takeaway from ESHRE 2026 is therefore not that one technology will transform IVF by itself.

Safer and more personalized care may increasingly depend on bringing evidence, fit-for-purpose technology, professional expertise, and patient-specific information together at each stage of treatment.

ESHRE 2026 Research Roundup by Kai Health